Arcus Biosciences (RCUS) Set to Announce Quarterly Earnings on Wednesday

Arcus Biosciences (NYSE:RCUS - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.02). Arcus Biosciences had a negative return on equity of 42.86% and a negative net margin of 100.81%. The business had revenue of $39.00 million during the quarter, compared to analysts' expectations of $26.24 million. During the same period in the prior year, the business posted ($1.04) EPS. The company's revenue was up 34.5% compared to the same quarter last year. On average, analysts expect Arcus Biosciences to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcus Biosciences Price Performance

Shares of RCUS stock traded down $0.41 during trading hours on Wednesday, hitting $16.00. The company had a trading volume of 350,821 shares, compared to its average volume of 727,243. Arcus Biosciences has a fifty-two week low of $12.95 and a fifty-two week high of $20.31. The company's fifty day moving average is $16.86 and its 200 day moving average is $16.02. The stock has a market capitalization of $1.46 billion, a PE ratio of -5.28 and a beta of 0.88.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on RCUS shares. Wells Fargo & Company began coverage on Arcus Biosciences in a report on Tuesday, October 8th. They issued an "overweight" rating and a $29.00 price objective on the stock. Wedbush reiterated an "outperform" rating and set a $30.00 price target on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Evercore ISI raised shares of Arcus Biosciences to a "strong-buy" rating in a research note on Friday, August 9th. Finally, Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an "overweight" rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $33.67.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.